tradingkey.logo

Veracyte Inc

VCYT
View Detailed Chart

34.110USD

+0.880+2.65%
Close 09/19, 16:00ETQuotes delayed by 15 min
2.68BMarket Cap
101.80P/E TTM

Veracyte Inc

34.110

+0.880+2.65%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.65%

5 Days

+10.46%

1 Month

+15.35%

6 Months

+7.33%

Year to Date

-13.86%

1 Year

-3.23%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
5 / 506
Overall Ranking
56 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Buy
Current Rating
41.222
Target Price
+24.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 50.32% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 24.14M.%!(EXTRA int=2)
Overvalued
The company’s latest PE is 99.74, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 84.22M shares, decreasing 2.21% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 8.08M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Ticker SymbolVCYT
CompanyVeracyte Inc
CEOMr. Marc A. Stapley
Websitehttps://www.veracyte.com/
KeyAI